Additionally, as the study was only 12 weeks in duration, it is possible that a longer duration of IL-1 inhibition, or perhaps treating patients with an earlier stage of CKD, may indeed alter markers of CKD-MBD and/or indices of physical and cognitive function. This evidence concerns the gene IL1B and chronic kidney disease.